# Diabetes Obesity and Metabolism

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/diabetes-obesity-and-metabolism/

## Facts

| Field | Value |
| --- | --- |
| APC (USD) | 4,940 |
| Citations | 240,631 |
| h-index | 186 |
| Homepage | http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1463-1326 |
| Open Access | false |
| ISSN-L | 1462-8902 |
| ISSNs | 1462-8902,1463-1326 |
| OpenAlex ID | https://openalex.org/S148394532 |
| Publisher | Wiley |
| Works | 7,929 |

## Journal papers

Showing 12 of 89.

- [Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension](https://scholariq.org/papers/weight-regain-and-cardiometabolic-effects-after-withdrawal-of-semaglutide-the/)
- [Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes](https://scholariq.org/papers/effects-of-empagliflozin-on-blood-pressure-and-markers-of-arterial-stiffness-and/)
- [Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis](https://scholariq.org/papers/efficacy-and-safety-of-sodium-glucose-co-transporter-2-inhibitors-in-type-2/)
- [Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis](https://scholariq.org/papers/why-do-scp-sglt2-scp-inhibitors-reduce-heart-failure-hospitalization-scp-a-scp/)
- [Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin](https://scholariq.org/papers/dapagliflozin-maintains-glycaemic-control-while-reducing-weight-and-body-fat/)
- [Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity](https://scholariq.org/papers/oxidative-stress-and-potential-interventions-to-reduce-oxidative-stress-in/)
- [Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes](https://scholariq.org/papers/interim-analysis-of-the-effects-of-exenatide-treatment-on-a1c-weight-and/)
- [Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: <scp>A</scp> systematic review and mixed‐treatment comparison analysis](https://scholariq.org/papers/efficacy-and-safety-of-glucagon-like-peptide-1-receptor-agonists-in-type-2/)
- [Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trials](https://scholariq.org/papers/effect-of-metformin-on-cardiovascular-events-and-mortality-a-meta-analysis-of/)
- [Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis](https://scholariq.org/papers/effect-of-sglt2-inhibitors-on-cardiovascular-renal-and-safety-outcomes-in/)
- [Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years](https://scholariq.org/papers/dapagliflozin-in-patients-with-type-2-diabetes-receiving-high-doses-of-insulin/)
- [Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trials](https://scholariq.org/papers/efficacy-and-safety-of-sodium-glucose-co-transport-2-inhibitors-in-type-2/)

## Journal top topics

Showing 8 of 25.

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Hyperglycemia and glycemic control in critically ill and hospitalized patients](https://scholariq.org/topics/hyperglycemia-and-glycemic-control-in-critically-ill-and-hospitalized-patients/)
- [Diabetes and associated disorders](https://scholariq.org/topics/diabetes-and-associated-disorders/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.